



21 May 2024

DorsaVi AI Natural Movement Algorithm (AI NMA) achieves gold-standard validation

Key Highlights:

- **dorsaVi's AI NMA has been validated to industry-leading Vicon's standards, paving way for entry into large disability diagnostics market**
- **Achievement underpinned by over 10 years of clinical and reference data collected by dorsaVi which is a source of proprietary movement pattern algorithms**
- **dorsaVi's sensor technology has been used to measure abnormal spinal movements in a chronic spinal pain clinical trial in Europe**
- **dorsaVi's sensor technology is now ready for commercial implementation by providing real-time postural impairment detection, alerts and insights to aid clinicians with large, unmet patient needs in disability care**

Melbourne, Australia, 21 May 2024: dorsaVi (ASX:DVL) (**dorsaVi** or the **Company**), developer of FDA cleared wearable sensors and leader in human movement analytics, is pleased to announce its AI Natural Movement Algorithm (AI NMA) has successfully validated the accuracy of its platform against the gold-standard in disability diagnostics by leveraging over a decade of data collection and analysis. dorsaVi can now commercialise its platform in the large disability market in line with the Company's commitment to improve the wellbeing of physically impaired individuals while increasing market share through ongoing product innovation.

As previously disclosed¹, dorsaVi successfully completed the integration of AI NMA into its existing sensor technology recently. dorsaVi's AI NMA is embedded into a sensor which provides data on rehabilitation progress, biomechanical efficiencies and creates personalised patient insights and assessments. dorsaVi's AI NMA was developed with over 10 years of data collected from inhouse clinical studies and strategic partnerships with major global healthcare providers. The AI NMA has been validated against Vicon's gold standard of movement analysis, which effectively enables dorsaVi to enter a range of markets, including the aged care sector.

AI NMA applications in disability diagnostics and management:

dorsaVi's extensive AI NMA database is a valuable and comprehensive resource adding to the normative dataset that has been cleared by the FDA, enabling the identification and analysis of abnormal movement patterns often associated with various disabilities and / or health conditions –

¹ See ASX release "dorsaVi enters aged care market with proprietary 'natural movement' AI algorithm on 16 April 2024

including patterns across gait, posture and range of motion for the lumbar, thoracic, and cervical spine. In addition, the database serves as a valuable reference to aid in the early detection and risk assessment of abnormal movement patterns, enabling the real-time capability to alert patients, provide predictive diagnostics and facilitate targeted interventions with the ultimate objective to improve patient outcomes.

As such, this positions dorsaVi at the forefront of leveraging advanced technology to address specific needs within the multifaceted disability market. An illustrative case where dorsaVi's sensor technology has the potential to make a significant positive impact is in the measurement and management of chronic spinal inflammatory conditions such as Ankylosing Spondylitis (AS), a debilitating inflammatory condition affecting the spine.

AS patients often experience early onset pain and stiffness throughout their spine due to inflammation and fusion of spinal segments over time. While medications may offer potential relief, current outcome measures for assessing spinal movements lack sensitivity and fail to capture subtle changes over extended periods – which adversely impact the efficacy measurement and assessment of medications. dorsaVi's sensors have been utilised on patients' spine as the key tool to measure clinical outcomes in a European AS clinical study. If the project is successful, ideally we would aim to work with the research group and pharma companies to provide research clinicians with clear methods, a proven sensor system and a fully validated score for the AS condition.

Ultimately, dorsaVi's innovative sensor technology extends its reach to any form of physical impairment, where maintaining proper posture presents a significant challenge. Using dorsaVi sensors integrated with AI NMA, enables continual monitoring to detect postural asymmetries early and gain invaluable real-time insights into posture dynamics which reduces the risk of associated complications, thereby improving overall patient safety and well-being.

Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, commented:

"We are excited about the potential of our sensor technology to make a meaningful impact in the disability and aged care sectors. By leveraging our extensive database and advanced AI algorithms, we aim to address unmet needs and improve the lives of individuals.

Ongoing research in debilitating conditions, such as Ankylosing Spondylitis, highlights the capability of dorsaVi's sensor technology and we look forward to further expanding our reach. dorsaVi continues to explore other use cases for its newly developed sensor technology, including the insurance, OH&S, and workplace safety markets – with the sensor technology commercially ready to implement at scale.

Clinicians and patients can be confident in dorsaVi's ability to drive positive outcomes through innovative technology and impactful solutions. These groundbreaking applications underpin dorsaVi's commitment to innovation and its mission to enhance individuals' quality of life.

This release has been authorised for lodgement to the ASX by the Company's Disclosure Committee.

– ENDS –

For further information about dorsaVi, please contact:

Company

Andrew Ronchi
Chief Executive Officer
T: +61 417 882 267
E: ar@dorsavi.com

Investors

Joel Seah
Vesparum Capital
T: +61 3 8582 4800
E: dorsavi@vesparum.com

About dorsaVi

dorsaVi Ltd (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is segmented into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com